ArticleNature medicine2026
COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental data suggest that COVID-19 vaccination could modulate immune checkpoint inhibitor (ICI) effects, but population evidence is limited. Using the French health data system (Système National des Données de Santé), we identified 95,015 adults initiating ICI therapy between December 2020 and March 2023. We assessed mRNA vaccination within 100 days before ICI initiation using inverse probability of treatment weighting and within 100 days after ICI initiation among previously unvaccinated patients using a cloning-censoring-weighting target-trial emulation. The primary outcome was all-cause mortality; secondary outcomes were cancer-specific and non-COVID-19 mortality. Follow-up extended to 31 December 2024 for all-cause mortality and to 31 December 2023 for cause-specific deaths. Pre-ICI mRNA vaccination was associated with lower early all-cause mortality (hazard ratio (HR) 0.90 (95% confidence interval (CI) 0.87-0.94) at 1-3 months and 0.96 (0.93-1.00) at 6 months) and no significant association after 12 months. Post-ICI mRNA vaccination showed a similar early association (HR 0.84 (95% CI 0.80-0.88) at 3 months and 0.86 (0.79-0.94) at 6 months), also with no significant association after 12 months. Estimates for non-COVID-19 and cancer-specific mortality were similar to those for overall survival. Similar early patterns with non-mRNA COVID-19 and other adult vaccines suggest modest, transient associations or healthy-vaccinee effects, rather than a specific mRNA COVID-19 vaccine effect.
Identifiers
42722885What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.